iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Shreehas Tambe assumes charge as MD -; CEO of Biocon Biologics

6 Dec 2022 , 12:09 PM

Biocon

Shreehas Tambe, Deputy CEO of Biocon Biologics, has been appointed as the Managing Director and CEO, effective December 5, 2022, of Biocon Biologics Limited (BBL), a subsidiary of Biocon Limited.

Tambe will guide BBL toward its goal of becoming a global biosimilar leader.

Tambe succeeds Arun Chandavarkar, who will continue to serve on the Board of Biocon Biologics as a non-executive, non-independent director.

Shreehas Tambe, Deputy CEO of Biocon Biologics since March 2021, has played an important and very effective role in assisting Arun Chandavarkar in steering the company toward sustainable growth and laying a strong foundation for the future.

Shreehas Tambe has been associated with Biocon since 1997, serving in a variety of leadership and operational roles. He has helped build and shape Biocon's biosimilars business over the last 25 years, as well as spearheading the Group's strategic capital investments, including its first overseas facility in Malaysia.

Shreehas has also been instrumental in obtaining regulatory approvals and successfully launching several of the company's biosimilar assets in global markets such as the United States and the European Union.


At around 10.47 AM, Biocon was trading at Rs276.55 down by 0.9% from its previous closing of Rs279.05 on the BSE. The scrip opened at Rs279.95 and touched intraday high and low of Rs280.30 and Rs276.20 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Biocon Biologics
  • Biocon news
  • Biocon results
  • Biocon Share
  • Biocon Stock
  • Biocon Updates
  • BioconSharePrice
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

Indices end the day in red
21 Jun 2024|07:00 PM
Zepto raises $665 million
21 Jun 2024|07:01 PM
Market Update: Nifty and Sensex Dip
21 Jun 2024|01:47 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.